undamentalytics Newsletter
Sign in

Collegium Pharmaceutical, Inc revenue

Collegium Pharmaceutical, Inc's revenue was $781m in fiscal 2025, up 23.6% on the year before. Since fiscal 2016 ($1.7m) it has grown at a compound 97.5% a year. Over the last twelve months it was $808m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue228280297310277464567631781808
Growth on the year before—+>999%+884.7%+5.8%+4.5%−10.7%+67.6%+22.2%+11.4%+23.6%—
Gross profit126115103180151209326377463485
Gross margin87.6%90.9%40.9%34.7%58.0%54.4%45.2%57.5%59.8%59.3%60.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Belbuca $222M 28.4% ▲ 4.9%
Xtampza ER $199M 25.5% ▲ 4.2%
Jornay Pm $149M 19.1% ▲ 299.7%
Nucynta IR $115M 14.8% ▲ 14.5%
Nucynta ER $81M 10.4% ▲ 6.9%
Symproic and Other $14.5M 1.9% ▼ 4.3%

From Collegium Pharmaceutical, Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Collegium Pharmaceutical, Inc $808m 14.3% 14.6%
Corcept Therapeutics Inc $831m 16.0% 24.7%
Supernus Pharmaceuticals, Inc. $865m 26.9% 12.3%
Axsome Therapeutics, Inc. $865m 54.2% 57.0%
Pacira Biosciences, Inc. $746m 5.7% 3.7%
Amphastar Pharmaceuticals, Inc. $730m 1.0% 10.5%

Compare with peers

Head to head: COLL vs CORTCOLL vs SUPNAXSM vs COLL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Collegium Pharmaceutical, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Collegium Pharmaceutical, Inc.